OTC : BTTX

Better Therapeutics, Inc.

$0.0001 USD

$0 (0.0%)

Volume
3K
Average Volume
4.11K
Market Capitalization
$5.45K
P/E Ratio
0.00
Dividend Yield
0.00%
Price Target
Year High
$0.00
Year Low
$0.00
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$1.37
Company Overview

OTC

Craig R. Jalbert

Medical - Specialties

Healthcare

BTTX

54

US

USD

https://www.bettertx.com

415 887 2311

08773T104

0001832415

Liquidity Metrics

-16.55

1.37

1.37

1.17

0.00

Sales & Valuation

-$

0.00

0.00

0.00

-1.28

Profitability

-$1.69

-$39.76M

0.00%

0.00%

-221.99%

-173.30%

P/E Metrics

0.00

0.00

0.00

Analyst Price Target & Rating

N/A

0/5

2 Analysts

%

Financial Health Scores

-27.28

2/9

-$5.59M

$10.72M

$20.66M

-$29.61M

Key Metrics (TTM)

-$854.55K

0.00

0.02

1.37

-221.99%

-273.67%

-1687821.03%

-552274.39%

-406 days

Company Executives
Name Title
Mark A. Berman Chief Medical Officer
Andres Camacho Senior Vice President of Technology & Head of Engineering
Frank L. Karbe Interim Chief Financial Officer
Angela Willis Senior Vice President of Market Access
Jessica Meng Chief Commercial Officer
David Perry Co-Founder & Executive Chairman
Kristin Wynholds Chief Product Officer
Poll Results

No votes yet today — be the first to share your view!

About Better Therapeutics, Inc. (OTC:BTTX) Stock

Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company’s lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. In addition, the company’s clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis ,and chronic kidney disease. Its product pipeline also includes BT-002, which intends glyc ... emic control for hypertension; BT-003 to reduce LDL cholesterol in patients with hyperlipidemia; and BT-004, which intends to explore the impact of treatment on liver health in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease. The company was founded in 2015 and is headquartered in San Francisco, California.

Frequently Asked Questions

What is the current Better Therapeutics, Inc. (BTTX) stock price?

Better Therapeutics, Inc.(OTC:BTTX) stock price is $0.0001 in the last trading session. During the trading session, BTTX stock reached the peak price of $0.001 while $0.0001 was the lowest point it dropped to. The percentage change in BTTX stock occurred in the recent session was 0.0% while the dollar amount for the price change in BTTX stock was $0.

BTTX's industry and sector of operation?

The OTC listed BTTX is part of Medical - Specialties industry that operates in the broader Healthcare sector.

Who are the executives of BTTX?

Mark A. Berman | Chief Medical Officer
Andres Camacho | Senior Vice President of Technology & Head of Engineering
Frank L. Karbe | Interim Chief Financial Officer
Angela Willis | Senior Vice President of Market Access
Jessica Meng | Chief Commercial Officer

How many employees does BTTX have?

Number of BTTX employees currently stands at 54. BTTX operates from 548 Market Street, San Francisco, CA 94104, US.

Link for BTTX official website?

Official Website of BTTX is: https://www.bettertx.com

How do I contact BTTX?

BTTX could be contacted at phone #415 887 2311 and can also be accessed through its website. BTTX operates from 548 Market Street, San Francisco, CA 94104, US.

How many shares of BTTX are traded daily?

The average number of BTTX shares traded daily for last 3 months was 4.11K.

What is the market cap of BTTX currently?

The market value of BTTX currently stands at $5.45K with its latest stock price at $0.0001